25 results found.

Mesothelioma Clinical Trial using Nintedanib; Pemetrexed; Cisplatin; Placebo

Boehringer Ingelheim - Recruiting 18 years or older.
- Double Blind, Randomised, Multicentre, Phase II Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma.
Nintedanib; Pemetrexed; Cisplatin; Placebo

Advanced Cancer, Metastatic Cancer, Lymphoma, Metastatic Breast C Clinical Trial using LY3023414; Midazolam; Letrozole

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer.
LY3023414; Midazolam; Letrozole

Pseudomyxoma Peritonei, Colorectal Carcinoma, Ovarian Carcinoma, Clinical Trial using CRS-HIPEC

Oslo University Hospital - Recruiting 18 years or older.
- Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies..
CRS-HIPEC

Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
CB-839

Mesothelioma Clinical Trial using Pentostatin; Cyclophosphamide; SS1P

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot/ Phase II Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients With Mesothelioma.
Pentostatin; Cyclophosphamide; SS1P

Metastatic Cancer, Pancreatic Cancer, Mesothelioma, Ovarian Cance Clinical Trial using Fludarabine; Cycolphosphamide; Aldesleukin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes.
Fludarabine; Cycolphosphamide; Aldesleukin

Malignant Pleural Mesothelioma Clinical Trial using WT-1-vaccine Montanide + GM-CSF; Montanide adjuvant + GM-CSF

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy.
WT-1-vaccine Montanide + GM-CSF; Montanide adjuvant + GM-CSF

Mesothelioma Clinical Trial using Pemetrexed + Cisplatin or Carboplatin AUC=5 Pleurectomy/decortication (if feasible) Intensity Modulated Radiation Therapy

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Toxicity Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma..
Pemetrexed + Cisplatin or Carboplatin AUC=5 Pleurectomy/decortication (if feasible) Intensity Modulated Radiation Therapy

Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Ne Clinical Trial using Mithramycin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum.
Mithramycin

Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, S Clinical Trial using H1299 Lysate Vaccine; Cyclophosphamide; Celecoxib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum.
H1299 Lysate Vaccine; Cyclophosphamide; Celecoxib

Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uv Clinical Trial using tumor specimens

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Clinical and Histopathologic Characteristics of BAP1 Mutations.
tumor specimens

Mesothelioma Clinical Trial using Zometa (zoledronic acid)

University of Alabama at Birmingham - Recruiting 19 years or older.
- A Pilot Phase 2 Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Advanced Malignant Mesothelioma.
Zometa (zoledronic acid)

Malignant Pleural Mesothelioma Clinical Trial using defactinib (VS-6063); Placebo

Verastem, Inc. - Recruiting 18 years or older.
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma.
defactinib (VS-6063); Placebo

Advanced Malignant Pleural Mesothelioma Clinical Trial using Gemcitabine; Cysplatin

Instituto Nacional de Cancerologia de Mexico - Recruiting 18 years to 75 years.
- Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma..
Gemcitabine; Cysplatin

Mesothelioma Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma.

Malignant Pleural Mesothelioma Clinical Trial using Pre-op RT +/- chemotherapy

University Health Network, Toronto - Recruiting 18 years or older.
- A Feasibility Study Evaluating Neoadjuvant Hemithoracic Intensity Modulated Radiation Therapy for Surgically Resectable Malignant Pleural Mesothelioma.
Pre-op RT +/- chemotherapy

Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Can Clinical Trial using AdV-tk + valacyclovir

Advantagene, Inc. - Recruiting 18 years or older.
- A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion.
AdV-tk + valacyclovir

Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcom Clinical Trial using tivantinib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma.
tivantinib; laboratory biomarker analysis

Malignant Pleural Mesothelioma Clinical Trial using WT-1-vaccine Montanide + GM-CSF; Montanide adjuvant + GM-CSF

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy (MSK10-134).
WT-1-vaccine Montanide + GM-CSF; Montanide adjuvant + GM-CSF

Lung Cancer - Malignant Pleural Mesothelioma Clinical Trial using Ganetespib; Placebo

University College, London - Recruiting 18 years or older.
- A Phase I/II Study of First Line Ganetespib With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma.
Ganetespib; Placebo

Malignant Mesothelioma Clinical Trial using pemetrexed disodium; clinical observation

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients With Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy.
pemetrexed disodium; clinical observation

Lung Cancer, or Mesothelioma Clinical Trial

University Health Network, Toronto - Recruiting 30 years to 85 years.
- Early Diagnosis of Mesothelioma and Lung Cancer Following Asbestos Exposure Using Low-dose Computed Tomography.

Pleural Mesothelioma Clinical Trial using Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)

Columbia University - Recruiting 18 years to 75 years.
- Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol.
Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)

Mesothelioma Clinical Trial using Velcade (bortezomib) plus Eloxatin (oxaliplatin)

Columbia University - Recruiting 18 years or older.
- A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma.
Velcade (bortezomib) plus Eloxatin (oxaliplatin)

Mesothelioma Clinical Trial using Gemcitabine in long infusion

Institute of Oncology Ljubljana - Recruiting 18 years or older.
- Cisplatin With Either Alimta or Gemcitabine in Long Infusion for Mesothelioma: A Randomised Phase II Trial (AGILI Trial).
Gemcitabine in long infusion